- AU$2.74m
- AU$2.15m
- AU$0.62m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 4.5 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -410.65% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 0.93 | 0.63 | 0.77 | 0.9 | 0.62 | n/a | n/a | 9.46% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Opyl Limited is an Australia-based company that provides biopharma and health organizations access to artificial intelligence (AI)-assisted technologies and professional guidance to understand and improve healthcare design, development and delivery. It has two core business streams: services and technologies. Its technology research and development pipeline provide life science developers and healthcare providers with unprecedented insight and data optimization opportunities. It has three key platforms in development that utilize artificial intelligence to analyze structured and unstructured data to deliver high value insights. Its platforms include clinical trial prediction and protocol design tool, clinical trial recruitment tool (Opin) and deep social media insights in healthcare. Its core services accessible at it include clinical trial recruitment, social media insights, market research and analysis and training and workshops. Its Opin is a clinical trial recruitment platform.
Directors
- Julian Chick CHM
- Michelle Gallaher CEO
- Misha McPherson COO
- Damon Rasheed EDR
- Erik Norum OTH
- Scott Sorochak OTH
- Jason Weaver OTH
- David Lilja SEC
- Mark Ziirsen DRC (58)
- Megan Robertson NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 17th, 1994
- Public Since
- March 7th, 1996
- No. of Employees
- 3
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 124,527,257.09
- Address
- Engine House, 105 Wellington Street, ST KILDA, 3182
- Web
- https://www.shareroot.co/
- Phone
- +61 894209300
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for OPL
Similar to OPL
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:16 UTC, shares in Opyl are trading at AU$0.02. This share price information is delayed by 15 minutes.
Shares in Opyl last closed at AU$0.02 and the price had moved by -23.55% over the past 365 days. In terms of relative price strength the Opyl share price has underperformed the ASX All Ordinaries Index by -28.79% over the past year.
There is no consensus recommendation for this security.
Opyl does not currently pay a dividend.
Opyl does not currently pay a dividend.
Opyl does not currently pay a dividend.
To buy shares in Opyl you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.02, shares in Opyl had a market capitalisation of AU$2.74m.
Here are the trading details for Opyl:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: OPL
Based on an overall assessment of its quality, value and momentum Opyl is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opyl. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -53.42%.
As of the last closing price of AU$0.02, shares in Opyl were trading -33.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Opyl PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Opyl's management team is headed by:
- Julian Chick - CHM
- Michelle Gallaher - CEO
- Misha McPherson - COO
- Damon Rasheed - EDR
- Erik Norum - OTH
- Scott Sorochak - OTH
- Jason Weaver - OTH
- David Lilja - SEC
- Mark Ziirsen - DRC
- Megan Robertson - NED